Clinical trials: Protein Energy Wasting
End Stage Renal Disease, Kidney Disease
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).
- Conditions
- End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
- Trial name
- NCT01958970
- Testing
- PINTA 745
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pinta Biotherapeutics